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Dr Milladoi:10.1016/j.jtcvs.2005.10.048Objective: Epicardial, beating heart cryoablation for the treatment of atrial fibrilla-
tion may be limited by heat from intracardiac blood flow. We therefore evaluated the
ability to create cryolesions using an argon-based cryoclamp device, which tempo-
rarily occludes blood flow and facilitates transmurality.
Methods: Six mongrel dogs underwent sternotomy. A clamp employing a 10-cm
argon-based linear cryoablation device was used epicardially to isolate the pulmo-
nary veins and left atrial appendage. After clamping of lesions, the probe was
removed from the cryoclamp device, and the remaining linear lesions, analogous to
the Cox maze III, were performed. Pulmonary vein stenosis was evaluated with the
use of magnetic resonance imaging. Left atrial function and pulmonary venous flow
velocities were assessed with transesophageal echocardiography. Transmurality was
confirmed both electrically and histologically. Animals were then put to death at 30
days.
Results: All acute and chronic cryoclamp lesions produced conduction block. There
was no change in right (RPV) or left pulmonary vein (LPV) diameter on the basis
of magnetic resonance imaging at baseline and at planned death (RPV-1, 19.6 2.9
mm vs 16.9  2.8 mm, P  .22; RPV-2, 13.2  2.0 mm vs 11.8  1.6 mm, P 
.22; and LPV, 12.2  2.4 mm vs 11.2  1.9 mm, P  .30). Left atrial function and
pulmonary venous flow velocities were unchanged. Tissue sections determined trans-
murality in 93% of cryoclamp lesions and 84% of linear ablations performed with the
10-cm malleable probe.
Conclusions: Epicardial application of this cryoclamp device on the beating heart
produced transmural lesions, which persisted 30 days. Linear epicardial cryoabla-
tion was not as effective as the cryoclamp device at producing consistent transmural
lesions. This novel, versatile device may be useful in treating patients with atrial
fibrillation on the beating heart without cardiopulmonary bypass.
Atrial fibrillation (AF) is present in 1% of the general population, affectingover 2 million people in the United States.1 The prevalence of this arrhyth-mia has been increasing as the population ages, afflicting nearly 10% of
patients older than 80 years.2 AF is associated with significant morbidity through its
compromise of cardiac hemodynamics and increased risk of thromboembolic
events. The Cox maze III procedure was described by Cox and associates3 in 1991
and is considered the gold standard for the surgical treatment of AF. The procedure
involves a “cut-and-sew” technique, which is thought to direct reentrant circuits into
dead ends while allowing the normal propagation of sinoatrial stimuli. The long-
term success of the Cox maze III is well established with 96.6% freedom from AF
at a mean follow-up of 5.4 years.4 Despite the success of the Cox maze III with
regard to restoring sinus rhythm and preventing strokes and anticoagulant-related
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ETbleeding, it failed to gain widespread use, largely because of
its complexity, prolonged cardiopulmonary bypass time,
increased risk of bleeding from multiple suture lines, and
overall increased morbidity.5
As a means of avoiding the morbidity of the cut-and-sew
technique, new ablative devices that use cryo, radiofrequency,
microwave, ultrasound, and laser energy to block these reen-
trant circuits have been established. Cryoablation employs
freezing to ablate tissue by forming intracellular ice crystals.
These ice crystals irreversibly damage organelles leading to
cell death once the tissue has thawed.6Argon-based cryo-
Abbreviations and Acronyms
AF  atrial fibrillation
CS  coronary sinus
IVC  inferior vena cava
LA  left atrium
LAA  left atrial appendage
LPV  left pulmonary vein
PV  pulmonary vein
RA  right atrium
RAA right atrial appendage
RPV  right pulmonary vein
SVC  superior vena cava
TEE  transesophageal echocardiographyFigure 1. Clamp (A), linear probe (B), an
404 The Journal of Thoracic and Cardiovascular Surgery ● Febrthermy has been used to create endocardial lesions on the
arrested heart in patients with AF during concomitant car-
diac procedures.7,8 However, the ability to create transmural
epicardial cryolesions on the beating heart may be limited
by the heat from intracardiac blood flow. In this study, a
novel, 10-cm, argon-based cryoprobe and cryoclamp de-
vice, which can reach temperatures of 160°C, was eval-
uated in an off-pump beating heart canine model, to deter-
mine whether both the clamp device and the linear probe are
able to produce transmural lesions without causing pulmo-
nary vein stenosis or left atrial (LA) dysfunction.
Materials and Methods
Study Design
All procedures were done with the approval of the Institutional
Animal Care and Use Committee (IACUC) of Weill Medical
College of Cornell University. The dogs received humane care in
compliance with the “Guide for the Care and Use of Laboratory
Animals” published by the National Institutes of Health (NIH
Publication No. 85-23, revised 1996). The funding agency did not
participate in data interpretation. This study consisted of 6 adult
mongrel dogs with a mean age of 14.6 months and weight of 25 to
30 kg. All dogs underwent a preoperative transesophageal echo-
cardiogram (TEE) to assess baseline LA function and pulmonary
vein (PV) flow velocities. In addition, preoperative cardiac-gated
magnetic resonance imaging (MRI) was performed to image the
PVs. On the night before surgery, the dogs were started on an oral
carprofen regimen (4.4 mg · kg1 · d1), which continued untild assembled cryoclamp device (C).
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ETpostoperative day 5. Acepromazine (0.01 mg/kg) and atropine
(0.05 mg/kg) were administered subcutaneously for sedation; in-
travenous thiopental (5 mg/kg) and inhaled isoflurane were used
for induction and anesthesia maintenance, respectively. Antibiotic
prophylaxis was administered. A femoral arterial line and electro-
cardiogram were used for continuous hemodynamic assessment. A
median sternotomy was performed and the pericardium was
opened. Before the PV dissection was begun, a phenylephrine
infusion was titrated to assist in hemodynamic control while the heart
was being manipulated. The PVs were then dissected free and encir-
Figure 2. Diagram of a canine heart with the cryoabla
posterior side of the heart and the lesions performed on
anterior view of the heart and right atrium. Circles repre
Figure 3. A, Intraoperative view of the clamp devic
appendage (large black arrow). B, The cryoclamp was
the right atrial appendage (black arrow head).
The Journal of Thoracicled with umbilical tape, and a bolus of heparin was administered
intravenously (100 U/kg).
Clamp Cryoablation Lesions
A cryoclamp, which houses a 10-cm linear cryoprobe, was used
epicardially on the beating heart (Figure 1). The lesion-set con-
sisted of an atrial cuff adjacent to the ostia of the left pulmonary
veins (LPVs; Figure 2). Next, the superior and inferior right
pulmonary veins (RPVs) and the base of the left atrial appendage
esion-set. The left side of the image demonstrates the
eft atrium. The right side of the image demonstrates the
cryoclamp lesions; lines represent linear cryolesions.
rforming a cryolesion at the base of the left atrial
disassembled and the linear probe was used to ablatetion l
the l
sente pe
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ET(LAA) were cryoablated individually (Figure 3). The clamp lesions
were tested for conduction block with an epicardial pacing
device.
Linear Cryoablation Lesions
The clamp was then disassembled and the 10-cm malleable probe
was used to create linear lesions on both the right atrium (RA) and
LA (Figures 2 and 3). All lesions were applied for a total of 3
minutes each, irrespective of the probe temperature. The lesions
included a connecting lesion from the LAA to the LPV and from
the LPV to the mitral annulus. For technical reasons, the RPV-to-
LPV connecting lesion was not performed. The right atrial lesions
included a superior vena cava (SVC) to inferior vena cava (IVC)
lesion, a right atrial appendage (RAA) to the IVC, and an IVC to
a tricuspid valve annulus. Care was taken to avoid injury to the
circumflex and right coronary arteries when performing lesions to
the valve annulus. The circumflex and right coronary arteries were
identified and left in situ. We did not attempt to dissect the
coronary artery from the epicardial fat or retract it in any way.
Great care was exercised to avoid contacting the vessels with the
probe during ablation. The pericardium was then closed. A chest
tube was placed into the left pleural space, and the sternum
reapproximated with wires.
Postoperative Care
Postoperative care consisted of pain management with a 75-g
fentanyl patch for 72 hours, oral carprofen for 5 days, and inter-
mittent doses of subcutaneous hydromorphone as needed. Oral
antibiotics were continued until postoperative day 2, when the
chest tube was removed. The dogs survived for 30 days. Before the
dogs were returned to the operating room for planned death and
TABLE 1. Cryoclamp ablation
Lesion
Mean
temperature* (°C)
Time to
–40°C (s)
Electrical
isolation†
Lesion
width (cm)
LPV 48.5 2.9 64.2  9.7 100% 0.5 0.1
LAA 53.2 7.4 50.8  13.6 100% 0.7 0.1
SRPV 55.4 17.3 52.6 22 100% 0.6 0.1
IRPV 68.5 16.8 34 18.9 100% 0.5 0.1
CI, Confidence interval; IRPV, inferior right pulmonary vein; LAA, left atrial a
temperature represents the temperature reached at the end of the 20-sec
voltage output. ‡Percentage of tissue sections with full transmurality is g
TABLE 2. Right and left atrial linear cryoablation
Lesion
Mean
temperature* (°C)
Probe
length (cm)
Lesion
length (cm)
Lesio
width
RAA 124 24.6 6.7 1.8 4.8 1.2 0.8 
SVC to IVC 113 13.0 7.6 1.2 3.4 0.7 1.0 
Tricuspid annulus 135 18.6 3.2 0.4 1.7 0.5 0.6 
LAA to LPV 146 3.1 2.2 0.2 1.1 0.2 0.8 
Coronary sinus 143 6.3 2.3 0.3 1.4 0.6 0.6 
CI, Confidence interval; IVC, inferior vena cava; LAA, left atrial appendage;
*Mean temperature for linear lesions represents the temperature at the
transmurality is given along with the 95% confidence intervals. ‡One lesion wa
406 The Journal of Thoracic and Cardiovascular Surgery ● Febrtissue harvest, postoperative TEE and MRI were performed to
compare with baseline studies.
Planned Death and Tissue Harvest
The chest was reopened through the previous sternotomy and the
pericardial space was reentered. The PVs and LAA were dissected
free and again test-paced to assess for conduction block. A lethal
dose of pentobarbital was then administered. The heart and lungs
were removed en bloc. Gross inspection of the atria and PVs
was made to identify lesions, inspect for mural thrombi, and to
assess for PV stenosis. The entire sample was then immersed in
10% formalin for 24 hours before sectioning for histopathology.
Data Acquisition
Cryoablation. The cryoclamp consists of a 10-cm, argon-
based, malleable probe (CryoCath Technology, Montreal, Quebec,
Canada), which fits into a clamp device (Figure 1). Both the probe
and the clamp have a thermostat, which displays real-time tem-
peratures on the console. For the clamp lesions, once the cryoc-
lamp was placed into position, a 20-second dose was applied as
soon as the tissue temperature reached 40°C. The temperatures
recorded are those at the end of the 20-second dosing period (Table
1). The temperatures described for the linear lesions are the final
temperatures at the end of the 3-minute ablation (Table 2).
Electrical isolation. Unipolar epicardial pacing was done with
a Pacesetter (Sylmar, Calif) temporary cardiac pacemaker. A pac-
ing lead (Medtronic Minneapolis, Minn) was used to connect the
pacemaker box to a 24-inch Temporary Cardiac 2-0 Pacing Wire
(Genzyme, Cambridge, Mass). Baseline pacing in all areas of the
heart, including PVs, was 1 volt. Electrical isolation was defined as
Tissue
thickness
Completely
transmural lesions
Transmurality
(tissue sections)
Transmurality‡
(95% CI)
20  0.03 83% (5/6) 96% (23/24) 79%-100%
33  0.06 50% (3/6) 70% (12/17) 44%-90%
14  0.02 100% (6/6) 100% (26/26) 87%-100%
15  0.03 100% (6/6) 100% (18/18) 81%-100%
age; LPV, left pulmonary vein; SRPV, superior right pulmonary vein. *Mean
osing period. †Acute and 30-day chronic electrical isolation with maximal
long with the 95% confidence intervals.
Tissue
thickness (cm)
Completely
transmural lesions
Transmurality (% of
tissue sections)
Transmurality†
(95% CI)
0.30 0.05 50% (3/6) 76% (22/29) 56%-90%
0.18 0.05 67% (4/6) 91% (20/22) 71%-99%
0.25 0.11 20% (1/5)‡ 75% (9/12) 43%-95%
0.23 0.06 100% (6/6) 100% (10/10) 69%-100%
0.92 0.19 0% (0/0) 40%§ —
left pulmonary vein; RAA, right atrial appendage; SVC, superior vena cava.
of the 3-minute dosing period. †Percentage of tissue sections with full0.
0.
0.
0.
ppend
ond dn
(cm)
0.3
0.3
0.1
0.1
0.2
LPV,
ends sectioned longitudinally. §Longitudinal sections.
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ETthe inability to pace distal to the lesion with a maximal output of 10
volts.
Transesophageal echocardiography. A 5-MHz TEE (Acuson,
Mountain View, Calif) was used with an XP Acuson echocardio-
graphic system. The mitral valve was examined for anatomic
abnormalities and function with 2-dimensional and color flow
Doppler. The LV inflow velocities were recorded at the tips of the
mitral valve leaflets with the use of a sample volume of 5 mm.
Color flow Doppler was used to align the ultrasonography beam
with the direction of blood flow. The following diastolic LV inflow
velocities were identified: early (E), after the beginning of diastole,
and late (A), during atrial contraction. The left and right PVs were
then identified with the use of 2-dimensional echocardiography
and color flow Doppler. The systolic (S) and diastolic (D) veloc-
ities were recorded. When systolic velocities consisted of more
than 1 peak, the highest was recorded.
Figure 4. Magnetic resonance imaging with axial (A)
(white arrow). No evidence of pulmonary vein stenosi
Figure 5. A, Gross picture of the right pulmonary vein a
at the cryoclamp lesion completely encircling the ope
Histologic slide of the cryoclamp lesion stained wi
transmural lesion. Black arrowhead shows the transiti
stains red, while connective tissue stains blue.
The Journal of ThoraciMagnetic resonance imaging. MRI of the PVs was obtained
with the use of a 3-Tesla scanner and V.H.3.0 software (General
Electric, Milwaukee, Wis). All dogs were sedated with a single
dose of pentobarbital (30 mg/kg) and intubated for airway
control. Cine cardiac-gated MR images were obtained with an
image matrix of 256  192 or 256  256 pixels, echo time (TE)
3.4, repetition time (TR) of 8.8, flip angle of 30°, and slice
thickness of 6 mm. The images were acquired in the trans-
verse, coronal, and sagittal planes to visualize the PVs. Cross-
sectional images of the PVs were then used to measure vessel
diameters (Figure 4).
Histopathology. After tissue harvest, the heart and lungs were
immersed in 10% formalin for 24 hours. The right and left atria
were splayed open, and the ostia of the PVs and LAA were
identified (Figure 5). Linear cryolesions performed with the 10-cm
cryoprobe were identified and measured directly with a tape mea-
oronal (B) views of the right superior pulmonary vein
seen.
n from within the left atrium. Large black arrow points
of the RPV leading to complete conduction block. B,
asson’s trichrome. Large black arrow points at the
f left atrium to pulmonary vein. Viable cardiac muscleand c
s iss see
ning
th M
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ETsurer. Both clamp lesions and linear epicardial lesions were ex-
cised from the heart as a single intact lesion. The circular clamp
lesions were cut open so as to convert a circular lesion to a linear
lesion by cutting open the vein along its length. All lesions were
then cut into 2- to 3-mm cross sections and placed on the embed-
ding cartridge. The entire length of the lesion was used, which in
some cases required more than 1 cartridge. The sections were then
placed in the cartridge in sequential order. The tissue sections were
stained with both hematoxylin and eosin, and Masson’s trichrome
and were interpreted by a veterinary pathologist. The results are
expressed as the percentage of tissue sections with fully transmural
lesions.
Statistical Analysis
Continuous variables are reported as mean SD. A 2-tailed paired
Student t test was performed when comparing preoperative and
postoperative MRI and TEE results. Estimates of rates and 95%
confidence intervals, and of mean within-dog changes in variables
and 95% confidence intervals of these changes, are given.
Results
Operative Results
All PV and LAA lesions were made with a single applica-
tion of the cryoclamp (Table 1). Electrical isolation was
found in both acute and chronic lesions. The clamp device
allowed for complete encirclement of all left PVs. The LA
appendage was clamped at its base and ablated (Figure 3).
The right PVs were clamped individually.
For the linear lesions, mean probe length used for the RA
and LA lesions was 6.0  2.5 cm and 2.8  1.1 cm,
respectively. Mean final temperatures for these lesions were
124.5°C  20.4°C and 139.2°C  16.2°C, respectively.
Longer segments of probe exposed to the tissue lead to warmer
temperatures at the end of the dosing period (Table 2).
TABLE 3. Assessment of pulmonary vein stenosis and left
Preablation
Transesophageal echocardiography
Transmitral flow (E/A ratio) 1.8 0.4
Pulmonary vein velocity (cm/s)
RPV systolic 37.2 14.
RPV diastolic 53.6 18.
LPV systolic 32.5 10.
LPV diastolic 57.2 14.
Magnetic resonance imaging
Vessel diameter (mm)
SRPV 19.6 2.9
IRPV 13.2 2.0
ILPV 12.2 2.4
E/A ratio, Early diastolic filling/late diastolic filling ratio during atrial contra
left pulmonary vein; RPV, right pulmonary vein; SRPV, superior right pulm
estimate, upper; P value).All dogs survived the 30-day study period.
408 The Journal of Thoracic and Cardiovascular Surgery ● FebrMRI
Cine MRI of the PVs was obtained in coronal, axial, and
sagittal views (Figure 4). Preoperative and postoperative
images were then compared to evaluate for PV stenosis.
None of the postoperative images identified a stenotic le-
sion. In addition, measurements of the preoperative and
postoperative images did not demonstrate significant
changes in PV diameters (Table 3).
TEE
The same investigator performed all TEE studies. No sig-
nificant change in LA systolic function (E/A ratio) was
found: E/A at baseline vs sacrifice, 1.78  0.4 vs 1.62 
0.3, P  .49. The atrial systolic velocity was comparable
between the 2 groups (A wave preablation, 46.7  13.2
cm/s vs A wave postablation, 36.7  6.8 cm/s; P  .25).
There were no significant changes on PV flow velocities
between preablation and postablation studies (Table 3).
Postmortem Analysis
Visual inspection of the clamp lesions to the PV and LAA
did not demonstrate stenosis or endoluminal thrombi (Fig-
ure 5). Lesion width ranged from 0.4 to 0.7cm. All PV
tissue sections demonstrated 100% transmurality, whereas
70% of LAA sections were fully transmural (Table 1). All
linear lesions were readily identified on gross inspection.
Linear lesion width ranged from 0.5 to 1.6 cm (Table 2).
Final pathologic examination demonstrated full transmural-
ity in 84% of the tissue sections (Figure 6). Figure 6
demonstrates examples of nontransmural linear cryolesions.
Linear lesions performed from the inferior LPV across the
coronary sinus (CS) to the mitral annulus demonstrated
segments of full transmurality in 4 of 6 dogs (Figure 7). The
l function
Postablation Within-dog mean change
1.6  0.3 0.70,0.15,0.40; 0.49
27.5  9.9 23, 9.7, 4.1; 0.15
57.9 20.9 11, 4.3, 19.0; 0.54
28.9  11.4 12, 2.2, 8.0; 0.63
57.8 19.5 18, 4.0, 26; 0.69
16.9  2.8 8.1, 2.8, 2.6; 0.22
11.8  1.6 4.0, 1.4, 1.3; 0.22
11.2  1.9 3.5, 1.0, 1.4; 0.30
ILPV, inferior left pulmonary vein; IRPV, inferior right pulmonary vein; LPV,
y vein. *Within-dog mean change with 95% confidence intervals (lower,atria
4
0
7
1
ction;
onarlesions to the CS were sectioned parallel to the lesion so as
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ETto clearly define the depth of penetration below the CS.
With this type of sectioning, it is conceivable that the slide
may not represent an equal plane along the lesion; therefore,
it may not demonstrate full-thickness transmurality, which
may be a limitation to the CS lesion analysis. The tricuspid
annulus lesions were cut into cross sections, which may be
a more sensitive way of determining lesion transmurality.
Discussion
Previous experience with cryoablation technology has been
limited for epicardial ablation on beating hearts.9 This lim-
itation may be attributable to the heat-sink effect, which
may prevent sufficient cooling for the creation of transmural
lesions. This new ablation technology uses argon gas, lead-
ing to tissue temperatures as low as 160°C, which aids in
combating the heat-sink effect. In addition, the use of a
clamp device further decreases the heat sink by temporarily
occluding blood flow. After a single cryoablative dose, the
clamp device was able to effectively achieve electrical
isolation in both the PV and LAA. After a 30-day survival
Figure 6. Histologic cross sections of linear epicardial
right and left atria. Tissue sections are stained with
tissue, and red stain shows viable myocardium. Solid a
atrial appendage to left pulmonary veins connecting l
Right atrial appendage lesion (RAA) demonstrating are
appendage. C, Superior vena cava to inferior vena
mid-portion of the lesion with viable myocardium. D, T
points to the nontransmural segment.period, we did not find significant differences in preopera-
The Journal of Thoracitive and postoperative MRI PV diameters to suggest PV
stenosis as a result of the clamp lesions. In addition, PV
flow peak velocities and transmitral flow velocities mea-
sured by TEE did not show evidence of PV stenosis or LA
dysfunction. However, we do acknowledge that our sample
size was small and the power to detect small differences, if
present, was therefore low.
The histologic results of the clamp lesions are compa-
rable with other animal studies in which bipolar radio-
frequency was used.11,12 Histologic assessment of clamp
cryolesions demonstrated nearly 100% transmurality in PV
clamp lesions, with the exception of the LAA lesions, which
had 5 of 17 (29.4%) tissue sections with nontransmural
lesions. These tissue sections demonstrated thin regions of
subendocardial sparing, particularly in the thicker trabecu-
lated regions of the LAA. Despite this finding, the LAA
demonstrated complete conduction block on test pacing
(Table 1). However, even though test pacing was performed,
we do acknowledge that we cannot prove for certain that we
had local capture on test pacing, as we did not attempt to record
ns performed with the 10 cm malleable probe on both
on’s trichrome. Blue color demonstrates fibrotic scar
points to viable myocardium within the lesion. A, Left
(LAA con) demonstrating complete transmurality. B,
viable myocardium in the trabeculated regions of the
lesion (SVC to IVC) demonstrating a region at the
pid flutter lesion with subendocardial sparing. Arrowlesio
Mass
rrow
esion
as of
cava
ricuselectrograms in the isolated LAA or PV. One of the important
c and Cardiovascular Surgery ● Volume 131, Number 2 409
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ETprinciples in performing ablative procedures for AF is the
creation of lesions that are transmural.13 While the Cox maze
III assures 100% transmurality with cut-and-sew lesions, only
bipolar radiofrequency is reliable in ensuring 100% transmu-
rality.12 Endocardial cryoablation on the arrested heart pro-
vides the most optimum condition for transmural lesion with a
smooth endocardial surface, and without heat dissipation from
the intracardiac blood flow. Epicardial ablation on the beating
heart, however, introduces the heat sink of intracardiac blood
flow; in addition to epicardial fat, which prevents good tissue
contact with the probe.14 Although these thin subendocardial
regions of cardiac tissue were spared, the relevance of this is
unknown, as these lesions continued to demonstrate complete
conduction block.
A similar phenomenon was noted in a dog study with the
Figure 7. Histologic longitudinal sections of cryolesion
coronary sinus and mitral valve annulus. Tissue se
demonstrates fibrotic scar tissue, and red stain show
fibrotic replacement along the epicardium, with suben
rality seen only in the right-most portion of the lesion,
been completely spared. Black areas represent arti
including the CS. Atrial tissue below the CS has been s
lesion and the CS. E, Transmural ablation of the CS an
of the CS has been spared completely. F, Transmural
tissue below the investing fat have been spared com
coronary sinus; MV, mitral valve; V, ventricle.use of microwave energy to create a single circular lesion to
410 The Journal of Thoracic and Cardiovascular Surgery ● Febrisolate the PVs.10 The investigators were able to achieve
nearly 100% electrical isolation of the PVs in both acute and
3-week survival dog models. On histologic analysis, how-
ever, a mean of 33% transmurality was seen in the acute
lesions, while the 3-week survival lesions demonstrate a
mean 66% transmurality. The investigators concluded that
lesions leading to electrical isolation are an effective means
of blocking atrial conduction, despite being histologically
incomplete. Linear lesions to both right and left atria also
did not lead to 100% transmurality in all tissue sections.
Areas of thickened tissue such as the RAA lead to the
highest failure rates, and thinner tissue had more transmural
tissue sections (SVC to IVC). While tissue thickness likely
played a factor in these results, the length of the probe
exposed to the tissue also led to warmer temperatures, and
ending from the left inferior pulmonary vein across the
s are stained with Masson’s trichrome. Blue color
able myocardium. A, Nontransmural lesion showing
rdial sparing. Partial ablation of the CS. B, Transmu-
ding the CS. Atrial tissue below the investing fat has
C, Transmural ablation of nearly the entire lesion,
d. D, Nontransmural ablation of the right portion of the
tissue below the CS. Atrial tissue to the right and left
ion of the right portion of the slide. The CS and atrial
ely. A, Atrium; CCA, circumflex coronary artery; CS,s ext
ction
s vi
doca
inclu
fact.
pare
d the
ablat
plettherefore decreased its efficacy, leading to failures (Table 2).
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ETShort lesions with thin tissue such as the LAA to LPV
lesions led to 100% transmurality. Furthermore, although 4
of 6 LPV to mitral annulus lesions demonstrated areas of
complete transmurality, none of these lesions demonstrated
full transmurality throughout the entire length of the lesion.
Cardiac tissue underneath the CS moving toward the annu-
lus remained viable in all instances. Reasons for this failure
include the presence of thick regions of epicardial fat in the
interatrial groove, close proximity of the circumflex coro-
nary artery preventing adequate probe alignment, and tech-
nical limitations of the prototype probe. To avoid injury to
the circumflex artery, we were careful to avoid any contact
with the vessel, which prevented adequate position to ablate
the region of cardiac tissue underneath the CS. In addition,
the tip of this prototype probe had nearly a half-centimeter
region that did not cool as well as the rest of the probe. We
believe this played a factor in preventing the creation of
fully transmural lesions in this anatomic region. Modifica-
tions have since been made to avoid this limitation.
As with most animal studies, data from this study cannot
be directly extrapolated to the human heart, whose tissue
thickness and fat content are different. Although it appears
that this ablation device was able to produce transmural
lesions in this dog model, we cannot extrapolate this infor-
mation to predict the degree of transmurality achievable in
a human heart, which may be affected by chronic conditions
such as rheumatic heart disease and long-standing mitral
regurgitation. Most, but not all, lesions of the Cox maze III
procedure were performed in this study. The LPV to RPV
connecting lesion was not performed because of the ana-
tomic proximity of the inferior pulmonary veins. Such close
proximity may have led to an inability to differentiate the
clamp lesions from the linear connecting lesion.
In conclusion, recent advances in technology have led to
the creation of ablative devices that can replace the cut-and-
sew technique used in the Cox maze III procedure. Cryoc-
lamp ablation of the PVs and LAA in this canine model
resulted in lesions with complete conduction block. Linear
epicardial cryoablation using the 10-cm linear probe dem-
onstrated transmurality in 85% of the tissue sections. Thus,
compared with the CC device, linear epicardial cryoablation
was not as effective at producing consistent transmural
lesions.
This novel cryoablation probe and clamp device may
offer yet another option for cardiac surgeons performing
The Journal of Thoraciablative procedures to treat AF. With this prototype, the
clamp and probe easily disassemble and reassemble, allow-
ing the surgeon to perform both clamp ablations and linear
ablations with a single instrument. Future prototypes of this
cryothermy technology may increase further the ability to
perform transmural lesions via an epicardial approach on a
beating heart, which may then continue to improve mini-
mally invasive approaches using cryothermy.
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